Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clear Messages From Part D: Managed Care Learns to Work With Retail Pharmacists

This article was originally published in RPM Report

Executive Summary

Medicare drug plans and retail pharmacy groups are working together to clean up the mess that plagued the launch of Part D. The manufacturers should pay attention: the result may be new force in drug selection and adherence.

You may also be interested in...



A Powerful Demonstration: MTM May Be Counterpoint To Pricing Complaints

A proposed “enhanced” model for Medication Therapy Management in Medicare Part D draws rave reviews from a House subcommittee. The prospect of using medication better to lower overall costs is a great counterpoint to headlines about excessive drug prices.

When Interests Align: Medication Adherence

When you think about the impact of the Food & Drug Administration’s focus on real-world drug safety, the disruptive implications of the Affordable Care Act, and the relentless pressure to find savings in health care, it is easy to see the dangers posed to biopharma companies. But those forces aren’t all negative. In fact, they are helping to mobilize government, consumer groups and payors to push hard on at least one decidedly pro-pharma agenda: improving adherence with prescription medicines.

Keeping the Government at Bay: Protecting Part D from the Protected Classes and Specialty Drug Pricing

A tenuous collaboration between drug manufacturers and health insurance plans holds together Part D, the private Medicare drug benefit. That collaboration is coming under pressure on several fronts: specialty drug pricing and restrictions on health plan formulary tools for six specfic drug classes are the most threatening. Karen Ignagni, the head of the health industry trade group, says industry must resolve the problems or leave a hole for more government control.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel